Ubamatamab represents a highly specialized bispecific T-cell engaging antibody specifically engineered to bridge the structural gap between MUC16-expressing malignant ovarian cancer cells and cytotoxic T-lymphocytes by maintaining stable engagement with the CD3 receptor complex to evaluate the induction of tumor-specific immune responses across various preclinical experimental models in specialized oncology research environments.
Purity:
95.00%
CAS Number:
[2305629-50-7]
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted
